Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease (COPD)
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of informed consent prior to any study specific procedures
Male or female of non-childbearing potential (post-menopausal or surgically sterilised), age ≥40 years at Visit 1
Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD guidelines
Post-bronchodilator FEV1 ≥ 40 to \< 80% of the predicted normal value and post-bronchodilator FEV1/FVC \< 70%
Reversible airway obstruction
You may not be if
Significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the result of the study, or the patient's ability to participate in the study.
An exacerbation of COPD within 6 weeks prior to Visit 1
Treatment with systemic glucocorticosteroids with 6 weeks of Visit 2.
Recent or ongoing respiratory tract infection during enrolment period.
Need for long-term oxygen therapy and/or saturation O2 \< 92%.
